Asian Journal of Transfusion Science
Home About Journal Editorial Board Search Current Issue Ahead of print Back Issues Instructions Subscribe Login  Users: 516 Print this page  Email this page Small font sizeDefault font sizeIncrease font size 


 
LETTER TO THE EDITOR Table of Contents   
Year : 2011  |  Volume : 5  |  Issue : 1  |  Page : 56-57
Nanobiotechnology and blood substitutes


1 Department of Periodontology and Oral Implantology, Rural Dental College-Loni, Maharashtra, India
2 Department of Microbiology, Rural Dental College-Loni, Maharashtra, India
3 Department of Prosthodontics, Rural Dental College-Loni, Maharashtra, India

Click here for correspondence address and email

Date of Web Publication21-Jan-2011
 

How to cite this article:
Saini R, Saini S, Sharma S. Nanobiotechnology and blood substitutes. Asian J Transfus Sci 2011;5:56-7

How to cite this URL:
Saini R, Saini S, Sharma S. Nanobiotechnology and blood substitutes. Asian J Transfus Sci [serial online] 2011 [cited 2023 Mar 21];5:56-7. Available from: https://www.ajts.org/text.asp?2011/5/1/56/76004


Sir,

Nanobiotechnology is the assembling of biological molecules into 1-100 nm dimensions. These dimensions can be the diameter of nanodimension artificial cells or particles; membranes with nanodimension thickness or nanotubules with nanodimension diameter. [1] Since red blood cell (RBC) membrane includes blood group antigens, typing and matching are required earlier than they can be transfused into patients; these result in delays in emergency situations. The storage time using regular method is merely about 42 days. RBCs cannot be sterilized to remove infective agents like hepatitis viruses, HIV, and other probable emerging infective agents. Thus, RBCs substitutes are being developed. RBC contains hemoglobin (Hb), antioxidant enzymes, and multienzyme system to prevent the conversion of Hb into nonfunctioning met Hb. It has been shown as far back as 1957 that artificial RBC can be prepared with ultrathin polymer membranes of nanodimension thickness. To increase the circulation time, the first-generation engineered Hb is formed by using glutaraldehyde to crosslink Hb into soluble nanodimension polyhemoglobin (poly-Hb) that has been tested clinically in patients. Further extension includes conjugated Hb, intramolecularly crosslinked Hb, and recombinant Hb. For certain clinical uses, in addition to engineered Hb, antioxidants need to remove oxygen radicals to prevent injury from ischemia reperfusion. Nanobiotechnology is used to prepare second-generation engineered Hb by assembling Hb together with superoxide dismutase (SOD) and catalase (CAT) to form a nanodimension soluble complex of poly-Hb-CAT-SOD. A third-generation system is to prepare nanodimension complete artificial RBCs that can circulate for sufficient length of time after infusion. One approach uses lipid vesicles to encapsulate Hb. Another approach to use biodegradable polymer-like polylactic acid or a copolymer of polyethylene glycol-polylactide (PEG-PLA) to form the membrane of nanodimension completes artificial RBC. [2] Past experience has shown that it takes many years to develop ideas on blood substitutes into products and that lack of basic information has resulted in much failure and delays. It is important to carry out basic research to gain important basic information needed for the simultaneous development of blood substitutes. In the meantime, two types of first-generation nanodimension poly-Hb are in the final stages of clinical trials in human and one of these has been approved for routine clinical uses in patients in South Africa. New nanodimension-conjugated Hb is also being tested in clinical trial. Shortage of human Hb is being resolved by studies on recombinant human Hb, placenta Hb, bovine Hb, and synthetic heme. Meanwhile, new generations of modified Hb are being developed that can modulate the effects of nitric oxide for those clinical applications that might have potential problems related to oxygen radicals. Poly-Hb can be crosslinked to an enzyme to suppress the growth of tumor. A further development is the use of PEG-lipids or PEG-biodegradable polymer membranes to prepare nanodimension artificial RBCs containing Hb and complex enzyme systems. Many other extensions and modifications of this general principle of blood transfusion in nanobiotechnology are possible.

 
   References Top

1.Chang TM. Nanobiotechnology for hemoglobin blood substitutes. Crit Car Clin 2009;25:373-82.  Back to cited text no. 1
    
2.Chang TM. Blood replacement with nanobiotechnologically engineered hemoglobin and hemoglobin nanocapsules. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010;2:418-30.  Back to cited text no. 2
[PUBMED]  [FULLTEXT]  

Top
Correspondence Address:
Rajiv Saini
Department of Periodontology and Oral Implantology, Rural Dental College - Loni, Tehsil- Rahata, District- Ahmednagar, Maharashtra - 413 736
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0973-6247.76004

Rights and Permissions




 

Top
 
  Search

  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Email Alert *
    Add to My List *
* Registration required (free)  


    References

 Article Access Statistics
    Viewed3409    
    Printed167    
    Emailed0    
    PDF Downloaded60    
    Comments [Add]    

Recommend this journal

Association Contact us | Sitemap | Advertise | What's New | Copyright and Disclaimer | Privacy Notice


2006 - Asian Journal of Transfusion Science | Published by Wolters Kluwer - Medknow
Online since 10th November, 2006